TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Dose-Normalized Area Under the Concentration-Time Curve (AUC) of Vemurafenib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose-Normalized Maximum Observed Concentration (Cmax) of Vemurafenib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under concentration/time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of desaturation events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Changes in pelvic pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability as measured by the number of patients with adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Safety and tolerability as measured by the percentage of patients with adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants for whom iPSCs were created
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of Allodynia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Patient intention to visit a psychosocial counselor
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Photographs of back and spine radiographs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changing Il-17A levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Composite Endpoint of Onset of Kidney Failure, Sustained Decrease of eGFR ≥40%, or Renal Death
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: number of vasomotor symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in self-efficacy of symptom management
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in patient-provider communication
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Change in self-regulation of symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Hemoglobin mass lost
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Postoperative serum hemoglobin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Progression-free Rate
Endpoint domain: Mortality/survival
Primary endpoint: Therapeutic Success as Change From Baseline in Physical Functioning
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in sputum eosinophile-%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in neutrophile-%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of Adverse Events of grade 3 and 4
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants with Minimal Improvement in CGI-C Ratings
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Total [14C]- radioactivity (RA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major bleeding (TIMI definition)
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in HbA1C level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change of Multiplate ADPtest AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Recurrence of fistula
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in DHA content in human milk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Breastfeeding Success
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Length of telomere
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Senescence markers amount
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of rotavirus
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of surgical referral after treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Acid production in plaque
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sexual Quality of Life-Male (SQOL-M)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Sexual Quality of Life-Female (SQOL-F)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: International Index of Erectile Function (IIEF)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Wolf's Motor Function Test (WMFT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Fugl Meyer Assessment Scale for upper extremity (FMA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Second-event-free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Safety Analysis and Monitoring of Toxic Death
Endpoint domain: Adverse events/effects
Primary endpoint: Percent Change in BMI in Excess of the 95th Percentile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spread of sensorial block
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change scores of Positive and Negative Syndrome Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma high sensitivity cardiac troponin I (hsTnI) concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cmax of Donepezil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-t of Donepezil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Neuro-cognitive Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Effectiveness of natalizumab in muscle biopsies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Effectiveness of natalizumab in manual muscle testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: CTRP 9 level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Safety of Ascorbic Acid
Endpoint domain: Adverse events/effects
Primary endpoint: Neck Disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Pain Pressure Thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total time of hospitalization
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: bronchopulmonary dysplasia (BPD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: IIEF questionnaire scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in PROMIS Anxiety survey scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of patients achieving a > 30% reduction in avg daily pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in worst pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of osteopenia/osteoporosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline in Maximum Urethral Closure Pressure (MUCP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Continuous ORI monitoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Nasal Peak Inspiratory Flow (NPIF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Safety of Sleeve Gastrectomy
Endpoint domain: Adverse events/effects
Primary endpoint: Immunogenicity (neutralising antibodies toward FVII)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Limitation of mouth opening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of local edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modification of facial contour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Participants With an Objective Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Intraocular Pressure (IOP) in Study Eye
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Best Corrected Visual Acuity (BCVA) by Early Treatment Diabetic Retinopathy Study (ETDRS) Visual Acuity Charts in Study Eye
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Change From Baseline in Average AM/PM Reflective Total Nasal Symptom Score (rTNSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inflammatory Cytokines and Chemokines Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Bone Remodeling Markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of CR + CRi
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of Falls
Endpoint domain: Adverse events/effects
Primary endpoint: Time until improvement of acute exacerbation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Social Problem Solving Skills
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Clinical Status of Participants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with safety assessments
Endpoint domain: Adverse events/effects
Primary endpoint: Examination of skin/soft tissue of injected knee
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Fibular Inclination Angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Tibial Inclination Angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Infection resolution rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Acute postoperative opioid use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Difference in Thiobarbituric Acid Reactive Substances (TBARS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Difference in Tumor Necrosis Factor Alpha (TNF-alpha)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Perceived barriers to cervical cancer screening
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 4-week prolonged abstinence from smoking cigarettes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Driver gene mutation frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: COVID-19 hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of Patients Who Develop Post-operative Seromas
Endpoint domain: Adverse events/effects
Primary endpoint: Flow index of the endometrial region
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in percentage of monthly heavy drinking days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clearance of Sugammadex by Dialysis as Measured by the Reduction Ratio (RR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clearance of Rocuronium by Dialysis as Measured by the Reduction Ratio (RR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute allograft rejections
Endpoint domain: Adverse events/effects
Primary endpoint: Safe transgastric access to the abdomen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Ability to visualize the abdominal wall
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Physiological changes in the circulatory and respiratory system
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of treatment related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change of constipation score from the baseline in the end of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Substance abuse severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of prostate cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Objective biological markers of light sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustain Virological Response (SVR12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Effective Concentration (EC 50) of GRO Alpha
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Effective Concentration of IL-8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Effective Concentration of MCP-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from baseline in PANSS total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in PANSS (Depression-C) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in CGI-S total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pulse rate (heart rate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: peripheral oxygen saturation (SpO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Platelet reactivity 24 hours after initial loading of clopidogrel
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Platelet reactivity 1 month after initial loading of clopidogrel
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: number of muscle cramps
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Pregnancies without ultrasound or genetic abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Change in Standardized Uptake Values (SUV) Max
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Demarcation line (DL) depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in maximum keratometry (K-max) in diopters (D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in central corneal thickness in (µm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: OMAS total
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neutrophils
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Endothelin-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Urinary NGAL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Inter-recti distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rectus abdominis thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients with Major Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients with Minor Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: magnitude of antibody responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rate of Clinical Benefit (Complete or Partial Response Plus Stable Disease)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Induction to delivery time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Marginal Bone Level Alteration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retention in Medication Treatment
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Percentage of Participants That Report at Least 1 Solicited Injection-site Adverse Event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants That Report at Least 1 Solicited Systemic AE
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants That Report at Least 1 Vaccine-related Serious Adverse Event (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Anti-pneumococcal Polysaccharide (PnPs) Serotype-specific Immunoglobin G (IgG) Geometric Mean Concentrations (GMC) for Each Serotype at 30 Days Post Toddler Dose (PTD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Dementia Knowledge Assessment Scale
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Approach to Dementia Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Sense of Competence in Dementia Care Staff scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Maslach Burnout Inventory
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Taiwan Simple Work Stress Scale
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Respiratory Heat Loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean SaO2 during total sleep time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptability: Number of Participants That Felt the Intervention Was Well-Received
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes and improvement in clinical condition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time from signal lighting and sounding to start swallowing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Compliance with ICU feeding protocol
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Level of haematological and biochemical markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Quantification of chromosomal aberrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Detection of biochemical markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Metabolomics markers levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Digit Symbol-Coding Test score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Physician's Withdrawal Checklist score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Performance reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute Lung Injury or Acute Respiratory Distress Syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Survival without severe neurosensory disability
Endpoint domain: Mortality/survival
Primary endpoint: Qualified success for lowering the IOP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Whole brain and medial temporal lobe atrophy rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of sessions and level of assistance for exoskeletal-assisted walking skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Treatment-Emergent Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Safety and effectiveness of Rutan 0.1
Endpoint domain: Adverse events/effects
Primary endpoint: Diagnostic Impact
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity and specificity of tcCO2 monitoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) / Recommended Dose (RD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Diagnostic accuracy in detecting CAD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: % of Participants Who Had Smoked Cigarette(s) in the Past 7 Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Local (T5) and distal (L4) Pressure pain thresholds (PPT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inter-observer reproducibility of ultrasound score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GPPASI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GCSI questionnaire score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Stabilization of Transthyretin Amyloid Cardiomyopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes